Loading clinical trials...
Loading clinical trials...
A Single Ascending Dose, Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SP-101 Via Nebulizer for the Treatment of Cystic Fibrosis (CF)
Conditions
Interventions
SP-101 and doxorubicin Cohort 1
SP-101 and doxorubicin Cohort 2
Locations
4
United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Boston Children's Hospital, Brigham & Women's Hospital
Boston, Massachusetts, United States
Columbia University
New York, New York, United States
Hospital at University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
September 16, 2024
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
November 25, 2024
NCT02417740
NCT06616857
NCT07108153
NCT02740868
NCT07303621
NCT07274631
Lead Sponsor
Spirovant Sciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions